MINNEAPOLIS--(BUSINESS WIRE)--Uromedica, Inc. announces the initiation of its FDA Investigational Device Exemption trial for ACT® to evaluate its safety and efficacy for treatment of female SUI.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results